Preclinical efficacy testing of three antivenoms against Naja ashei
venom-induced lethality

Okumu, Mitchel O; Mbaria, James M; Gikunju, Joseph K; Mbuthia, Paul G; Madadi, Vincent O; Ochola, Francis O; Maloba, Kenneth N; Nderitu, Joseph G

dc.contributor.author	Okumu, Mitchel O
dc.contributor.author	Mbaria, James M
dc.contributor.author	Gikunju, Joseph K
dc.contributor.author	Mbuthia, Paul G
dc.contributor.author	Madadi, Vincent O
dc.contributor.author	Ochola, Francis O
dc.contributor.author	Maloba, Kenneth N
dc.contributor.author	Nderitu, Joseph G
dc.date.accessioned	2022-06-27T07:27:55Z
dc.date.available	2022-06-27T07:27:55Z
dc.date.issued	2022-04
dc.identifier.citation	Okumu MO, Mbaria JM, Gikunju JK, Mbuthia PG, Madadi VO, Ochola FO, Maloba KN, Nderitu JG. Preclinical efficacy testing of three antivenoms against Naja ashei venom-induced lethality. Toxicon X. 2022 Apr 27;14:100124. doi: 10.1016/j.toxcx.2022.100124. PMID: 35518711; PMCID: PMC9065424.	en_US
dc.identifier.uri	https://pubmed.ncbi.nlm.nih.gov/35518711/
dc.identifier.uri	http://erepository.uonbi.ac.ke/handle/11295/161179
dc.description.abstract	This study aimed to determine the efficacy of Inoserp, Vins bioproducts, and South African Institute of Medical Research (SAIMR) polyvalent antivenoms in neutralizing Naja ashei venom-induced lethality in mice. The neutralization efficacy of the antivenoms were expressed as effective dose, median effective ratio, potency, normalized potency, volume, and the number of vials of antivenom required to neutralize 100 mg of Naja ashei venom (NAV).	en_US
dc.language.iso	en	en_US
dc.publisher	University of Nairobi	en_US
dc.rights	Attribution-NonCommercial-NoDerivs 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.subject	Antivenoms; Naja ashei; Neutralization; Potency; Snakebite.	en_US
dc.title	Preclinical efficacy testing of three antivenoms against Naja ashei venom-induced lethality	en_US
dc.type	Article	en_US